Tag - David Novak

Markets

Raymond James starts Medexus at OP; PT $5.50 (Canadian)

Raymond James initiated coverage of Medexus Pharmaceuticals (TSX:MDP) with an “outperform” rating and price target of $5.50 (Canadian). The stock closed at $3.32 on Feb. 18. Medexus is a fully integrated, specialty...

February 22, 2022

Markets

Raymond James starts Eupraxia Pharma at OP; PT $13 (Canadian)

Raymond James initiated coverage of Eupraxia Pharmaceuticals (TSX:EPRX) with an “outperform” rating and a $13 price target. The stock closed at $6.21 on April 12. Eupraxia aims to address the growing burden of...

April 13, 2021

Tag - David Novak

Raymond James starts Medexus at OP; PT $5.50 (Canadian)

Raymond James starts Eupraxia Pharma at OP; PT $13 (Canadian)

General

More